ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

PBAXU Phoenix Biotech Aquisition Corporation

10.37
0.00 (0.00%)
Jun 17 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 4.70
Ask Price 6.75
News -
Share Name Share Symbol Market Stock Type
Phoenix Biotech Aquisition Corporation PBAXU NASDAQ Trust
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 10.37 19:00:00
Open Price Low Price High Price Close Price Previous Close
10.37 10.37
Trades Shares Traded Average Volume
0 0 -
Last Trade Type Quantity Price Currency
- 0  10.37 USD

Phoenix Biotech Aquisition Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
36.54M 6.25M - 0 -2.54M -0.41 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Phoenix Biotech Aquisition

Date Time Source Heading
6/05/202416:13Edgar (US Regulatory)Form S-1/A - General form for registration of securities..
5/22/202407:00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]
5/17/202416:09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
5/16/202405:28Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form..
5/06/202416:11Edgar (US Regulatory)Form S-1 - General form for registration of securities under..
5/03/202415:30Edgar (US Regulatory)Form 8-K - Current report
5/01/202423:16Edgar (US Regulatory)Form EFFECT - Notice of Effectiveness
5/01/202415:45Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]
5/01/202415:13Edgar (US Regulatory)Form 8-K - Current report
4/26/202415:31Edgar (US Regulatory)Form S-1/A - General form for registration of securities..
4/15/202415:36Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statements
4/10/202415:06Edgar (US Regulatory)Form S-1 - General form for registration of securities under..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No PBAXU Message Board. Create One! See More Posts on PBAXU Message Board See More Message Board Posts

PBAXU Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company¿s proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the body¿s full immune repertoire to achieve optimized cancer therapy. Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.